News summary

We Are Witnessing the End of Obesity

Source: Youtube - Dr. Stan Bradfield • Published: 06 Oct 2026, 14:55

Summarized by Masters of Longevity from Youtube - Dr. Stan Bradfield.

Examines drivers of the obesity epidemic, highlights ultra-processed and hyperpalatable foods, and discusses pharmaceutical and hormonal advances changing weight management.

We Are Witnessing the End of Obesity
Key Takeaways
  • A 2018 NIH inpatient trial found participants ate ~500 extra calories daily on ultra-processed diets matched for nutrients.
  • Industry-formulated hyperpalatable products comprised about 62% of US foods and contributed to increased caloric intake.
  • Newer multi-hormone drugs including GLP-1 and amylin agonists are presented as transforming long-term obesity treatment options.
Read the full article at Youtube - Dr. Stan Bradfield ↗

Continue exploring

Recommended MoL Picks

MoL PickThe Next Obesity-Drug Race Is About What Weight You LoseRegeneron’s myostatin and activin A antibodies point to a sharper question for the GLP-1 era: not whether people can lose more weight, but whether medicine can preserve the tissue that makes weight loss healthier.MoL PickSemaglutide Extended Lifespan in Mice. What Would Make It a Human Longevity Drug?A new animal study sharpens an important question: when do benefits in a particular disease become evidence for a longer, healthier life?MoL PickApoB: The cholesterol signal LDL can missIn longevity medicine, the useful biomarkers are not always the exotic ones. ApoB is a relatively simple blood test that can sharpen cardiovascular prevention when LDL-C looks reassuring but particle burden remains high.